Welcome to our dedicated page for Sarepta Therapeutics SEC filings (Ticker: SRPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sarepta Therapeutics, Inc.'s SEC filings document an operating biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under SRPT. Form 8-K reports furnish quarterly and annual financial results, product revenue disclosures for ELEVIDYS and PMO therapies, and clinical or regulatory updates for Duchenne muscular dystrophy treatments and siRNA pipeline programs.
Other filings cover proxy governance, executive compensation, equity-award plans and leadership-transition disclosures. Material-event reports also describe capital-structure actions, including exchange agreements for convertible senior notes, issuance of new convertible notes, common stock consideration and related indenture terms.
Cristin Rothfuss, EVP and General Counsel of Sarepta Therapeutics (SRPT), received stock awards totaling 118,875 restricted stock units (RSUs) on a transaction dated 09/03/2025. The awards consist of 93,875 RSUs that vest 50% on 09/03/2026 and 50% on 09/03/2027 subject to continued service, and 25,000 performance-based RSUs that vest 100% on 09/03/2028 only if performance criteria are met and the Reporting Person remains in service. Each RSU represents the right to one share and the grants were reported with a $0 purchase price. Following these grants, the Reporting Person beneficially owned 139,985 shares.
Sarepta Therapeutics filed a Current Report on Form 8-K disclosing an indenture dated August 28, 2025 with U.S. Bank Trust Company, National Association as trustee that includes the form of a 4.875% Convertible Senior Note due 2030. The filing references the form of the note as included in Exhibit 4.1. The report is signed by Ian Estepan, President and Chief Operating Officer.
Sarepta Therapeutics filed an 8-K that references its quarterly report on Form 10-Q for the period ended June 30, 2025 and notes that forward-looking statements in the filing speak only as of the filing date. The filing includes a standard cautionary statement qualifying forward-looking language and is signed by Ian Estepan, President and Chief Operating Officer, dated August 21, 2025.
The notice functions as a routine corporate disclosure: it directs readers to the company’s subsequent SEC filings for updates and establishes the date of the forward-looking statement safe-harbor. No financial results, transactions, or new material agreements are disclosed in the provided text.
Sarepta Therapeutics announced the planned departure of Bilal Arif, its Executive Vice President and Chief Technical Operations Officer, as part of a strategic restructuring and pipeline prioritization. Mr. Arif served in the role through August 12, 2025, will remain a Special Advisor until his employment ends on September 16, 2025, and will provide consulting services through December 31, 2025. The company and Mr. Arif executed a Separation and Consulting Agreement dated August 12, 2025, under which he will receive a lump-sum severance payment of $576,700 and a consulting fee of $400 per hour. Outstanding equity awards will continue to vest while he remains employed or provides consulting services. The full agreement will be filed as an exhibit to the Company’s Quarterly Report for the quarter ended September 30, 2025.
Sarepta Therapeutics received a Schedule 13G/A from Capital International Investors disclosing a passive, beneficial holding of 524,146 common shares, equal to 0.5% of the 98,277,032 shares reported outstanding. The filing identifies Capital International Investors as a division of Capital Research and Management Company and related investment management entities and states that those entities are collectively deemed the beneficial owner of the position.
The report shows detailed control metrics: sole voting power for 523,807 shares, sole dispositive power for 524,146 shares and no shared voting or dispositive power. The filing also certifies the shares are held in the ordinary course of business and not to change or influence control of the issuer.
Sarepta Therapeutics (SRPT) Form 4 filing: Chief Technology Operations Officer Bilal Arif reported the award of 6,250 Performance Stock Units (PSUs) on 08/05/2025. The grant originates from a March 1 2024 PSU agreement; shares earned were approved by the Compensation Committee based on milestone achievement. The PSUs convert 1-for-1 into common stock and will vest on 03/01/2026, contingent on continued employment. Following the transaction, Arif directly holds 6,250 derivative securities; no shares were sold and no cash price was paid, indicating this is an incentive, not a market purchase. No changes to common-stock ownership were disclosed.
The filing signals ongoing executive retention and alignment with long-term performance targets but does not materially affect share count or near-term earnings. Investors typically view such equity awards as neutral unless unusually large relative to existing float.
Insider award: On 08/05/2025 Sarepta Therapeutics (SRPT) President of R&D and Tech Ops, Louise Rodino-Klapac, earned 6,250 Performance Stock Units (PSUs) according to a Form 4 filing. The PSUs stem from a grant dated 03/01/2024 and were unlocked after the Compensation Committee confirmed the company met specific milestones. No cash was paid (exercise price $0) and there were no share sales or disposals. All 6,250 PSUs remain un-vested and are scheduled to vest on 03/01/2026, contingent on continued employment. Following the transaction the executive beneficially owns 6,250 derivative securities directly. The filing signals milestone achievement but represents a small ownership change relative to Sarepta’s total share count, implying limited dilution or immediate market impact.
SRPT Form 4: routine tax-withholding sale
On 07/31/2025, Sarepta Therapeutics (SRPT) Chief Financial Officer Ryan Ho-Yan Wong reported the disposition of 327 common shares at $16.42 under transaction code “F,” which denotes shares surrendered to the company solely to satisfy payroll-tax obligations triggered by vesting of RSUs granted 07/30/2021. After the withholding transaction, Wong directly holds 17,328 SRPT shares; no derivative positions were listed.
The filing reflects a non-discretionary, tax-related share reduction rather than an open-market sale, and therefore carries limited signaling value regarding insider sentiment or the firm’s fundamentals.